Literature DB >> 21086361

[Synchronous bilateral percutaneous nephrolithotomy (PCNL)].

F Gigli, M A Cerruto, F Zattoni.   

Abstract

BACKGROUND. The management of bilateral renal stones still represents a therapeutic challenge and synchronous bilateral percutaneous nephrolithotomy (PCNL) appears to be a well tolerated, safe and relatively rapid procedure with a favorable cost-benefit ratio. The purpose of the present study is to report our experience in the synchronous percutaneous treatment of bilateral renal stones. METHODS. We retrospectively evaluated clinical files from 4 consecutive patients (BS, BE, OCB, FL), who underwent a synchronous bilateral PCNL, performed by the same operator (ZF), for the management of renal persistent and/or recurrent stones after extracorporeal shock wave lithotripsy, or other surgical maneuvers. From each patient's file we recorded a clinical history, any peri- and post-operative complication, any therapeutic resolution employed and the outcomes in terms of stones persistence/recurrence. RESULTS. Overall, 3 men (BS, BE, FL) and 1 woman (OCB), their age ranging from 31 up to 76 years, consecutively underwent synchronous bilateral PCNL. In 75% of cases a calcium- oxalate nephrolithiasis was found. We did not find any peri- or post-operative complication. All patients were stone-free after a mean follow-up of 12 months (range: 3-24 months). CONCLUSIONS. Synchronous bilateral PCNL is a relatively safe procedure; it may be performed in selected patients without increasing the morbidity of this surgical maneuver. The simultaneous treatment of the contra-lateral kidney may be taken into account only when the PCNL of the first side has been performed quickly and easily without any peri-operative complication.

Entities:  

Year:  2008        PMID: 21086361

Source DB:  PubMed          Journal:  Urologia        ISSN: 0391-5603


  1 in total

1.  Bilateral single-session retrograde intra-renal surgery: A safe option for renal stones up to 1.5 cm.

Authors:  Punit Bansal; Neeru Bansal; Anand Sehgal; Subhash Singla
Journal:  Urol Ann       Date:  2016 Jan-Mar
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.